ALCOX — Nicox SA Share News
0.000.00%
Last trade - 00:00- €32.43m
- €28.69m
- €16.77m
Brief: Nicox To Get USD 2 Mln Advance Payment From Ocumension Under Zerviate Agreement
Brief: Nicox Sees Top-Line Results Of NCX 4251 Blepharitis Trial In Sept.
Brief: Nicox's NCX 470 Shows Significant Intraocular Pressure Lowering In Dolomites Phase 2 Glaucoma Trial
Brief: Nicox's Licensee Bausch+Lomb Receives Approval For VYZULTA In UAE
Brief: Nicox's Completes Enrollment Of NCX 4251 Phase 2B Blepharitis Trial
Brief: Nicox Partners With Laboratorios Grin
Brief: Nicox Licensee Bausch + Lomb Launches Vyzulta In Taiwan, Approved In Qatar
Brief: Nicox Updates On Fera's Evaluation Of Naproxcinod
Brief: Nicox: USPTO Issues Notice Of Allowance For Latanoprostene Bunod
Brief: Nicox’S NCX 4251 Mississippi Phase 2B Blepharitis Trial Reaches 50% Enrollment
Brief: Nicox announces U.S. Patents For Latanoprostene Bunod Eligible For Patent Term Extension
Brief: Nicox Q1 Net Revenue At 0.6 Million Euros
Brief: Bausch Health And Nicox Say VYZULTA Is Approved In Brazil
Brief: Nicox’s NCX 470 Mont Blanc Phase 3 Glaucoma Trial Reaches 50% Enrollment Milestone
Brief: Nicox’S NCX 470 Gets Approval By Chinese Authorities For Local Start Of Denali Phase 3 Trial
Brief: Nicox FY Net Loss Narrows To 18.1 Million Euros
Brief: Nicox Announces Publication Of Pre-Clinical Efficacy Results On New Class Of IOP-Lowering Compounds
Brief: Nicox’S U.S. Licensee Eyevance Expands U.S. Promotion Of ZERVIATE In Agreement With Hikma
Brief: Nicox, Bausch Health: Vyzulta Gets Approved In South Korea